Biostem Technologies Inc
BioStem Technologies, Inc. engages in the development, manufacturing, and commercialization of placental-derived allografts for advanced wound care and regenerative therapies in the United States. It offers Vendaje, a structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje AC, a thicker structural tissue allograft used as a protective covering for soft tissue wou… Read more
Biostem Technologies Inc (BSEM) - Total Assets
Latest total assets as of September 2025: $62.39 Million USD
Based on the latest financial reports, Biostem Technologies Inc (BSEM) holds total assets worth $62.39 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Biostem Technologies Inc - Total Assets Trend (1999–2024)
This chart illustrates how Biostem Technologies Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Biostem Technologies Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Biostem Technologies Inc's total assets of $62.39 Million consist of 95.3% current assets and 4.7% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 16.3% |
| Accounts Receivable | $104.98 Million | 74.8% |
| Inventory | $1.82 Million | 1.3% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $224.14K | 0.2% |
| Goodwill | $244.63K | 0.2% |
Asset Composition Trend (1999–2024)
This chart illustrates how Biostem Technologies Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Biostem Technologies Inc's current assets represent 95.3% of total assets in 2024, an increase from 41.5% in 1999.
- Cash Position: Cash and equivalents constituted 16.3% of total assets in 2024, up from 0.6% in 1999.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 50.0% in 1999.
- Asset Diversification: The largest asset category is accounts receivable at 74.8% of total assets.
Biostem Technologies Inc Competitors by Total Assets
Key competitors of Biostem Technologies Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Biostem Technologies Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - Biostem Technologies Inc generates 2.15x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Excellent ROA - For every $100 in assets, Biostem Technologies Inc generates $ 22.71 in net profit.
Biostem Technologies Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.31 | 0.18 | 0.15 |
| Quick Ratio | 4.09 | 0.11 | 0.05 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $40.47 Million | $ -5.83 Million | $ -6.11 Million |
Biostem Technologies Inc - Advanced Valuation Insights
This section examines the relationship between Biostem Technologies Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.94 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 864.1% |
| Total Assets | $140.38 Million |
| Market Capitalization | $77.55K USD |
Valuation Analysis
Below Book Valuation: The market values Biostem Technologies Inc's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Biostem Technologies Inc's assets grew by 864.1% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Biostem Technologies Inc (1999–2024)
The table below shows the annual total assets of Biostem Technologies Inc from 1999 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $140.38 Million | +864.10% |
| 2023-12-31 | $14.56 Million | +320.04% |
| 2022-12-31 | $3.47 Million | +29.76% |
| 2021-12-31 | $2.67 Million | +0.12% |
| 2020-12-31 | $2.67 Million | -15.40% |
| 2019-12-31 | $3.15 Million | -26.65% |
| 2018-12-31 | $4.30 Million | +41.77% |
| 2017-12-31 | $3.03 Million | +10.78% |
| 2016-12-31 | $2.74 Million | -6.76% |
| 2015-12-31 | $2.94 Million | +567.09% |
| 2014-12-31 | $440.20K | -87.33% |
| 2011-12-31 | $3.47 Million | +28.89% |
| 2010-12-31 | $2.70 Million | +31.80% |
| 2009-12-31 | $2.05 Million | -66.30% |
| 1999-12-31 | $6.07 Million | -- |